Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019015487> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2019015487 endingPage "157" @default.
- W2019015487 startingPage "152" @default.
- W2019015487 abstract "Sildenafil citrate (Revatio) is approved for pediatric pulmonary arterial hypertension (PAH) in the European Union. A new pediatric formulation, 10 mg/mL sildenafil citrate powder for oral suspension (POS), was developed for pediatric PAH patients. Bioequivalence among the POS suspension (20 mg), the Revatio 20-mg commercial tablet, and the sildenafil citrate 2 × 10-mg clinical trial tablets was assessed. In this randomized, open-label study, 42 healthy adult volunteers received the 3 different sildenafil treatments, each in a single 20-mg oral dose, using a 3-way crossover design. Blood samples were collected at predefined times and analyzed for sildenafil plasma concentrations. Natural log-transformed sildenafil pharmacokinetic parameters (Cmax, AUClast, and AUC∞) were evaluated for bioequivalence using a mixed-effects model. Results were used to estimate relative bioavailability and construct 90% confidence intervals (CIs). Bioequivalence was concluded if the 90% CIs for Cmax, AUClast, and AUC∞ were wholly contained within 80% to 125%. All 90% CIs for the ratios of adjusted geometric means of Cmax, AUClast, and AUC∞ were within 80% to 125%, the prespecified bioequivalence criteria. All 3 formulations were well tolerated. In conclusion, the POS suspension, the commercial 20-mg Revatio tablet, and the 10-mg sildenafil tablets were all bioequivalent to one another when given at the equal doses." @default.
- W2019015487 created "2016-06-24" @default.
- W2019015487 creator A5001755280 @default.
- W2019015487 creator A5025470445 @default.
- W2019015487 creator A5046819681 @default.
- W2019015487 creator A5061372791 @default.
- W2019015487 creator A5082102963 @default.
- W2019015487 date "2012-09-12" @default.
- W2019015487 modified "2023-10-16" @default.
- W2019015487 title "A Randomized, Open-Label, 3-Way Crossover Study to Demonstrate Bioequivalence of Sildenafil Powder for Oral Suspension With Tablets Used Commercially and in Clinical Studies for the Treatment of Pulmonary Arterial Hypertension" @default.
- W2019015487 cites W1558292706 @default.
- W2019015487 cites W1697899995 @default.
- W2019015487 cites W1956875558 @default.
- W2019015487 cites W1968101595 @default.
- W2019015487 cites W1994010558 @default.
- W2019015487 cites W2030825915 @default.
- W2019015487 cites W2040774455 @default.
- W2019015487 cites W2109335746 @default.
- W2019015487 cites W2121376498 @default.
- W2019015487 cites W2148225708 @default.
- W2019015487 cites W2333059991 @default.
- W2019015487 cites W70417718 @default.
- W2019015487 doi "https://doi.org/10.1177/2160763x12455172" @default.
- W2019015487 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27121457" @default.
- W2019015487 hasPublicationYear "2012" @default.
- W2019015487 type Work @default.
- W2019015487 sameAs 2019015487 @default.
- W2019015487 citedByCount "3" @default.
- W2019015487 countsByYear W20190154872014 @default.
- W2019015487 countsByYear W20190154872022 @default.
- W2019015487 countsByYear W20190154872023 @default.
- W2019015487 crossrefType "journal-article" @default.
- W2019015487 hasAuthorship W2019015487A5001755280 @default.
- W2019015487 hasAuthorship W2019015487A5025470445 @default.
- W2019015487 hasAuthorship W2019015487A5046819681 @default.
- W2019015487 hasAuthorship W2019015487A5061372791 @default.
- W2019015487 hasAuthorship W2019015487A5082102963 @default.
- W2019015487 hasConcept C112705442 @default.
- W2019015487 hasConcept C126322002 @default.
- W2019015487 hasConcept C142724271 @default.
- W2019015487 hasConcept C181389837 @default.
- W2019015487 hasConcept C204787440 @default.
- W2019015487 hasConcept C22979827 @default.
- W2019015487 hasConcept C27081682 @default.
- W2019015487 hasConcept C2776768464 @default.
- W2019015487 hasConcept C42404028 @default.
- W2019015487 hasConcept C44249647 @default.
- W2019015487 hasConcept C71924100 @default.
- W2019015487 hasConcept C87813604 @default.
- W2019015487 hasConcept C98274493 @default.
- W2019015487 hasConceptScore W2019015487C112705442 @default.
- W2019015487 hasConceptScore W2019015487C126322002 @default.
- W2019015487 hasConceptScore W2019015487C142724271 @default.
- W2019015487 hasConceptScore W2019015487C181389837 @default.
- W2019015487 hasConceptScore W2019015487C204787440 @default.
- W2019015487 hasConceptScore W2019015487C22979827 @default.
- W2019015487 hasConceptScore W2019015487C27081682 @default.
- W2019015487 hasConceptScore W2019015487C2776768464 @default.
- W2019015487 hasConceptScore W2019015487C42404028 @default.
- W2019015487 hasConceptScore W2019015487C44249647 @default.
- W2019015487 hasConceptScore W2019015487C71924100 @default.
- W2019015487 hasConceptScore W2019015487C87813604 @default.
- W2019015487 hasConceptScore W2019015487C98274493 @default.
- W2019015487 hasIssue "4" @default.
- W2019015487 hasLocation W20190154871 @default.
- W2019015487 hasLocation W20190154872 @default.
- W2019015487 hasOpenAccess W2019015487 @default.
- W2019015487 hasPrimaryLocation W20190154871 @default.
- W2019015487 hasRelatedWork W2011337719 @default.
- W2019015487 hasRelatedWork W2349338867 @default.
- W2019015487 hasRelatedWork W2356698425 @default.
- W2019015487 hasRelatedWork W2357220270 @default.
- W2019015487 hasRelatedWork W2359939078 @default.
- W2019015487 hasRelatedWork W2364471871 @default.
- W2019015487 hasRelatedWork W2374069256 @default.
- W2019015487 hasRelatedWork W2381431760 @default.
- W2019015487 hasRelatedWork W2392383498 @default.
- W2019015487 hasRelatedWork W48952282 @default.
- W2019015487 hasVolume "1" @default.
- W2019015487 isParatext "false" @default.
- W2019015487 isRetracted "false" @default.
- W2019015487 magId "2019015487" @default.
- W2019015487 workType "article" @default.